



## Notification Waiver Determination

### Resonetics – Resolution Medical

<b>Acquisition</b>	<p>Resonetics, LLC (<b>Resonetics</b>) applied for a notification waiver in respect of its proposed acquisition of:</p> <ul style="list-style-type: none"><li>(i) 100% of the issued and outstanding voting securities of Arcline Resolution Blocker, Inc. (<b>Blocker</b>), which owns minority non-corporate interests of Resolution Medical MidCo, LLC (<b>Resolution Medical</b>), and</li><li>(ii) the remaining non-corporate interests of Resolution Medical, as described in the transaction documents provided as part of the application (the <b>Acquisition</b>).</li></ul>
<b>Determination</b>	<p>The Australian Competition and Consumer Commission has determined under section 51ABV(1)(a) of the <i>Competition and Consumer Act 2010</i> (Cth) that the Acquisition is not required to be notified.</p>
<b>Date of determination</b>	<p>11 March 2026</p>

<b>Parties to the Acquisition</b>	<p>Resonetics is a high technology manufacturer, supplying product and manufacturing services primarily to the medical device industry for medical device components, beginning at the prototyping phase through to contract manufacturing. Resonetics also designs and manufactures customised laser-based manufacturing and scientific equipment, and provides design and development services to life science companies. Resonetics is jointly controlled by CP Granite Holdings, L.P., an affiliate of The Carlyle Group Inc., and GTCR LP and Regatta Medical Holdings, LLC, affiliates of GTCR LLC, and is based in the US.</p> <p>Resolution Medical is a provider of integrated design and manufacturing solutions for the full lifecycle of complex medical devices. Resolution Medical is currently owned by Arcline Investment Management, LP and is based in the US.</p> <p>Resonetics and Resolution Medical supply input products and services to the medical device manufacturing industry. In Australia, Resonetics supplies component manufacturing services from overseas locations to Australian customers, while Resolution Medical supplies contract development, design and engineering services from overseas locations to Australian customers.</p>
<b>Explanation for determination</b>	<p>In making this notification waiver determination, the Australian Competition and Consumer Commission (the <b>ACCC</b>) has considered the information provided with the notification waiver application and had regard to the factors in section 51ABV(2)(b) of the <i>Competition and Consumer Act 2010</i> (Cth) (the <b>Act</b>).</p>

	<p>Based on the information provided in the application, the ACCC considers that the Acquisition is unlikely to give rise to any material lessening of competition. In particular:</p> <ul style="list-style-type: none"><li>a. Resonetics and Resolution Medical have a small presence in Australia, with Resonetics primarily focused on manufacturing and Resolution Medical on contract development, design and engineering</li><li>b. limited horizontal overlap or vertical relationship in Australia</li><li>c. there are alternative global suppliers of input products and services to the medical device manufacturing industry.</li></ul> <p>The ACCC has also had regard to the likelihood that, if the Acquisition were put into effect, the notification thresholds determined under section 51ABP(1) of the Act would apply.</p> <p>While the ACCC considers that the notification thresholds are likely to be met, given that material competition concerns are unlikely to arise, the ACCC has determined that the Acquisition is not required to be notified.</p> <p>The ACCC considers that the determination is consistent with the object of the Act and the interests of consumers in promoting competition.</p> <p>For more information about the ACCC's approach to considering notification waiver applications and to assessing competition effects more generally, see the ACCC's <a href="#">interim guidance on notification waivers</a> and <a href="#">merger assessment guidelines</a>.</p>
--	---

**Determination made by Commissioner Woodward pursuant to a delegation under section 25(1) of the Act**